GLP-1, obesity and metabolic trial summaries

Plain-English, clinically serious reviews of important trials — with what they showed, what they missed, and what they mean in practice.

EVIDENCE BRIEFINGS

Most commentary on medical trials tells you the headline result. It often says much less about who was studied, what the findings do and do not prove, and how they apply to real patients. This page brings together my reviews of major studies relevant to obesity medicine, metabolic health, deprescribing, and clinical data interpretation.

GLP-1 stopping and maintenance

Articles
SURMOUNT-1 Trial Summary: What Tirzepatide Actually Showed

A plain-English summary of SURMOUNT-1: how effective tirzepatide was in obesity, who the study applied to, and what it still did not answer.

Read More →
STEP 1 Trial Summary: What Semaglutide Actually Showed

A plain-English summary of STEP 1: how much weight semaglutide produced, who the trial applied to, and what it did not prove.

Read More →
What Happens When Tirzepatide Is Stopped? What SURMOUNT-4 Showed

A clear summary of SURMOUNT-4: what happened when tirzepatide was continued, what happened when it was withdrawn, and why that matters for maintenance.

Read More →
What Happens When Semaglutide Is Stopped? What STEP 4 Showed

A clear, evidence-led summary of STEP 4: what happened when semaglutide was continued, what happened when it was stopped, and why that matters clinically.

Read More →